Canada - English - Health Canada

baxter corporation - cyclophosphamide - powder for solution - 1000mg - cyclophosphamide 1000mg - antineoplastic agents

Canada - English - Health Canada

baxter corporation - cyclophosphamide - powder for solution - 2000mg - cyclophosphamide 2000mg - antineoplastic agents

United States - English - NLM (National Library of Medicine)

carver korea co ltd - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567) - adenosine 0.12 mg in 30 ml

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - bleomycin sulfate, quantity: 15000 iu - injection, powder for - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - palliation and treatment adjuvant to surgery and radiation therapy of the following neoplasms: = squamous cell carcinoma of the skin, head and neck, and oesophagus (primary indication). = squamous cell carcinoma of the larynx, penis and uterine cervix. = squamous cell carcinoma of the bronchus (response infrequent). = choriocarcinoma and embryonal cell carcinoma of the testis. = advanced hodgkin's disease and other lymphomas. = mycosis fungoides.,note. use of bleomycin after radiation therapy is less successful than use before radiation therapy. bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated.

Canada - English - Health Canada

pfizer canada ulc - inotuzumab ozogamicin - powder for solution - 0.9mg - inotuzumab ozogamicin 0.9mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - bleomycin sulfate, quantity: 15000 iu - injection, powder for - excipient ingredients: - bleomycin is used for palliation and/or treatment adjuvant to surgery and radiation therapy and in the management of the following neoplasms: squamous cell carcinoma of the skin, head and neck, and oesophagus is the primary indication for bleomycin. tumour response has been obained in a number of patients with squamous cell carcinoma of the penis, larynx and uterine cervix. infrequent response has been shown in squamous cell carcinoma of the bronchus. treatment of choriocarcinoma and embryonal cell carcinoma of the testis is also indicated. bleomycin has been effectively used in advanced hodgkin's disease and in some cases of other lymphomas such as non-hodgkin's, and also in cases of mycosis fungoides.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lipegfilgrastim 10 mg/ml;  ;   - solution for injection - 6 mg/0.6ml - active: lipegfilgrastim 10 mg/ml     excipient: acetic acid polysorbate 20 sodium hydroxide sorbitol water for injection - reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - inotuzumab ozogamicin 1mg - powder for injection - 1 mg - active: inotuzumab ozogamicin 1mg excipient: polysorbate 80 sodium chloride sucrose trometamol - besponsa is indicated for the treatment of adults with relapsed or refractory cd22-positive b-cell precursor acute lymphoblastic leukaemia (all).

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - inotuzumab ozogamicin - powder, for solution - inotuzumab ozogamicin 1mg/vial

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

sanofi-aventis south africa (pty) ltd - injection - each 1 ml solution contains lenograstim 33,6 miu (263 micrograms)